Alliance Global Partners lowered the firm’s price target on Canopy Growth to C$0.60 from C$3.50 and keeps a Neutral rating on the shares. Canopy’s recent efforts to address some of its near-term balance sheet concerns provided the company some breathing room, but EBITDA losses and cash burn will likely persist in the near-term and the firm cautions on future dilution to shareholders or incremental strategic initiatives, such as divestitures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CGC:
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Largest borrow rate increases among liquid names
- Rising High: Exclusive talk with biotech company Enveric Biosciences
- Canopy Growth files to sell 13.22M common shares for holders
- Canopy Growth Tanks on Non-compliance Letter from Nasdaq